{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:07:53Z","timestamp":1789693673131,"version":"4.0.1"},"reference-count":26,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,16]]},"DOI":"10.14797\/mdcvj.1231","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T12:56:17Z","timestamp":1684241777000},"page":"50-56","source":"Crossref","is-referenced-by-count":4,"title":["Transcatheter Mitral Valve Replacement with Dedicated Devices"],"prefix":"10.14797","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-1630","authenticated-orcid":false,"given":"Joe","family":"Aoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-6132","authenticated-orcid":false,"given":"Michael J.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6041-3876","authenticated-orcid":false,"given":"Sachin S","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"2","key":"key20230516090256_B1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2013.08.723","article-title":"Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need","volume":"63","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"key20230516090256_B2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/eurheartj\/ehm001","article-title":"What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?","volume":"28","year":"2007","journal-title":"Eur Heart J"},{"issue":"3","key":"key20230516090256_B3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/ejcts\/ezaa109","article-title":"A tensed Tendyne","volume":"58","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"key20230516090256_B4","first-page":"E37","article-title":"Successful repositioning of apically tethered transcatheter mitral valve replacement in the off-bypass, beating heart","volume":"95","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"issue":"12","key":"key20230516090256_B5","doi-asserted-by":"crossref","first-page":"e1065","DOI":"10.4244\/EIJ-D-19-00333","article-title":"Mitral regurgitation severity predicts one-year therapeutic benefit of Tendyne transcatheter mitral valve implantation","volume":"15","year":"2019","journal-title":"EuroIntervention"},{"issue":"19","key":"key20230516090256_B6","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jacc.2021.08.060","article-title":"2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation","volume":"78","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"key20230516090256_B7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jacc.2016.10.068","article-title":"Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation: A Global Feasibility Trial","volume":"69","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"key20230516090256_B8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2018.12.066","article-title":"Initial Feasibility Study of a New Transcatheter Mitral Prosthesis: The First 100 Patients","volume":"73","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"key20230516090256_B9","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT); 2023 Mar 23 [cited 2023 Apr 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03433274"},{"issue":"3","key":"key20230516090256_B10","first-page":"287","article-title":"Transcatheter Mitral Valve Replacement with Intrepid","volume":"8","year":"2019","journal-title":"Interv Cardiol Clin"},{"issue":"1","key":"key20230516090256_B11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jacc.2017.10.061","article-title":"Early Experience With New Transcatheter Mitral Valve Replacement","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20230516090256_B12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcin.2021.10.018","article-title":"30-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results","volume":"15","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"key20230516090256_B13","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP) ; 2018 Nov [cited 2023 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01960348"},{"issue":"2","key":"key20230516090256_B14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jcin.2018.10.056","article-title":"Transcatheter Mitral Valve Replacement With a New Supra-Annular Valve: First-in-Human Experience With the AltaValve System","volume":"12","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"key20230516090256_B15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaccas.2019.10.034","article-title":"Transcatheter Mitral Valve Therapy With Novel Supra-Annular AltaValve: First Experience in the United States","volume":"1","year":"2019","journal-title":"JACC Case Rep"},{"key":"key20230516090256_B16","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Early Feasibility Study of the Neovasc TiaraTM Mitral Valve System (TIARA-I); 2022 Jan 18 [cited 2023 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02276547"},{"issue":"11","key":"key20230516090256_B17","first-page":"1239","article-title":"Percutaneous Transcatheter Mitral Valve Replacement: First-in-Human Experience With a New Transseptal System","volume":"73","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"key20230516090256_B18","doi-asserted-by":"crossref","first-page":"B8","DOI":"10.1016\/j.jacc.2019.08.030","article-title":"Updated 30-Day Outcomes for the U.S. Early Feasibility Study of the SAPIEN M3 Transcatheter Mitral Valve Replacement System","volume":"74","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"key20230516090256_B19","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.jcin.2020.06.040","article-title":"Transcatheter Mitral Valve Replacement With the Transseptal EVOQUE System","volume":"13","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"key20230516090256_B20","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Edwards EVOQUE Eos MISCEND Study; 2023 Jan 23 [cited 2023 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02718001"},{"issue":"20","key":"key20230516090256_B21","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jcin.2020.08.006","article-title":"Early Experience With a Novel Transfemoral Mitral Valve Implantation System in Complex Degenerative Mitral Regurgitation","volume":"13","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"key20230516090256_B22","article-title":"First-in-Human Implant of the Cephea Transseptal Mitral Valve Replacement System","volume":"12","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"19_Supplement_S","key":"key20230516090256_B23","first-page":"B78","article-title":"TCT-191 HighLife Trans-Septal Mitral Valve Replacement (TSMVR) System; Early and Long Term Clinical and Hemodynamic Outcomes of the First 30 Consecutive Cases; The HighLife Feasibility Studies in Europe, Australia, and the US","volume":"78","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"key20230516090256_B24","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. HighLifeTM Transcatheter Mitral Valve Replacement System Study; 2022 Sep 15 [cited 2023 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974881"},{"key":"key20230516090256_B25","unstructured":"Innovalvemed.com [Internet]. Ramat Gan, Israel; c2023. Our Technology; 2023 [cited 2023 Apr 25]. Available from: https:\/\/www.innovalvemed.com\/technology\/"},{"key":"key20230516090256_B26","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. TVMR With the Innovalve System Trial - Early Feasibility Study (TWIST-ESF); 2022 Dec 23 [cited 2023 Apr 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04919980"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T13:03:19Z","timestamp":1684242199000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1231\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5,16]]}},"alternative-id":["10.14797\/mdcvj.1231"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1231","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}